The particular molecular features of early EGFR+ lung cancers and their potential impact on TKI efficacy now acquire direct clinical relevance due to the recent promising results of the ADAURA study, which might lead to routine adjuvant administration of osimertinib in the near future (37). This evidence concerns the gene EGFR and lung carcinoma.